Objectives: Mutation analysis by massive parallel sequencing (MPS) is routinely performed in the clinical management of lung cancer in Sweden. We describe the clinical and mutational profiles of lung cancer patients subjected to the first 1.5 years of treatment predictive MPS testing in an autonomous regional health care region... Conclusion: Although the increasing importance of MPS as a predictor of response to targeted therapies is indisputable, its role in prognostics or as a predictor of clinical course in nontargetable advanced stage lung cancer requires further investigation. READ ARTICLE
JTO Clinical and Research Reports DOI:10.1016/j.jtocrr.2020.100013
Authors: Sofi Isaksson, Bassam Hazem, Mats Jönsson, Christel Reuterswärd, Anna Karlsson, Håkan Griph, Jens Engleson, Gudrun Oskarsdottir, Ronny Öhman, Karolina, Holm, Frida Rosengren, Karin Annersten, Göran Jönsson, Åke Borg, Anders Edsjö, Per Levéen, Hans Brunnström, Kajsa Ericson Lindquist, …Maria Planck
